Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up ...

• Main Authors: Clark, Paul J., Valery, Patricia C., Ward, James, Strasser, Simone I., Weltman, Martin, Thompson, Alexander, Levy, Miriam T., Leggett, Barbara, Zekry, Amany, Rong, Julian, Angus, Peter, George, Jacob, Bollipo, Steven, McGarity, Bruce, Sievert, William, Macquillan, Gerry, Tse, Edmund, Nicoll, Amanda, Wade, Amanda, Chu, Geoff, Harding, Damian, Cheng, Wendy, Farrell, Geoff, Roberts, Stuart K.
• Format: Article in Journal/Newspaper
• Language: unknown
• Published: figshare 2022
• Subjects: Medicine; Science Policy; Mental Health; Infectious Diseases; FOS Health sciences; First Nations
• Online Access: https://dx.doi.org/10.6084/m9.figshare.c.6092149; https://springernature.figshare.com/collections/Hepatitis_C_treatment_outcomes_for_Australian_First_Nations_Peoples_equivalent_SVR_rate_but_higher_rates_of_loss_to_follow-up/6092149

Abstract Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Methods Adults who initiated DAA therapy at one of 26 hospitals across Australia, 2016–2019 were included in the study. Clinical data were obtained from medical records and the Pharmaceutical and Medicare Benefits Schemes. Outcomes included sustained virologic response (SVR) and loss to follow-up (LTFU). A multivariable analysis assessed factors associated with LTFU. Results Compared to non-Indigenous Australians (n = 3206), First Nations Peoples (n = 89) were younger (p < 0.001), morel likely to reside in most disadvantaged (p = 0.002) and in regional/remote areas (p < 0.001), and had similar liver disease severity. Medicines for mental health conditions were most commonly dispensed among First Nations Peoples (55.2% vs. 42.8%; p = 0.022). Of ...